Johnson & Johnson (JNJ)
3 Dividend Aristocrats to Scoop Up During Market Pullbacks in June
If you are worried about the economy and how the market will move from here, it is ideal to invest in dividend stocks that pay, no matter the market situation. When you have dividend aristocrat stocks in your portfolio, you can ensure consistent payouts for years.
J&J must pay $260 million in latest talc trial, Oregon jury says
Johnson & Johnson must pay $260 million in the case of an Oregon woman who said she got mesothelioma from inhaling the company's talc powder, a jury found on Monday.
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO
Rapport Therapeutics is targeting a valuation of about $637 million in its initial public offering in the United States, as the biopharmaceutical company joins a slew of firms looking to list their shares amid a rebound in the capital markets.
3 Magnificent Dividend Stocks to Buy and Hold Forever
Johnson & Johnson is a Dividend King that's investing heavily in R&D and making smart acquisitions. Target is another Dividend King that continually looks for new ways to boost sales.
Johnson & Johnson: Market Will Regret The Overreaction
Johnson & Johnson stock prices have been consistently declining in the recent 1~2 years. The stock is currently undervalued, with lower P/E ratios compared to the sector median and historical averages, and a high dividend yield. Yet, Johnson & Johnson's profitability remains strong, and there are potential catalysts for growth, including the adoption of new products and potential acquisitions.
Boring Is Beautiful: 3 Blue-Chip Stocks to Buy and Hold Forever
As someone who has been actively investing for several years, I can tell you that it's natural to be drawn to thrilling investment opportunities promising impressive returns. However, I've learned that while the appeal of these opportunities is strong, embracing the stability of “boring” stocks often proves to be the wiser course of action.
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
Johnson & Johnson (JNJ) closed the most recent trading day at $145.28, moving +0.58% from the previous trading session.
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript)
Johnson & Johnson (NYSE:JNJ ) Bernstein's 40th Annual Strategic Decisions Conference Call May 29, 2024 1:30 PM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright Okay. Thanks, everybody.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate
J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.
